Apomorphine Hydrochloride

  • #LGM Pharma is a Apomorphine Hydrochloride CAS# 41372-20-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 41372-20-7
  • AHFC code:
  • Synonyms:
  • ATC Code: G04BE07 N04BC07
  • Chemical Formula: C17H17NO2
  • Molecular Weight: 267.3224
  • Assay/Purity: Typically NLT 98%
  • DrugBank: APRD00531
  • SMILES: [H][C,]12CC3=C(C(O)=C(O)C=C3)C3=CC=CC(CCN1C)=C23
  • InChl: InChI=1S/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1
  • PubChem: 6005
  • IUPAC: (9R)-10-methyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(16),2(7),3,5,13(17),14-hexaene-3,4-diol

Additional Details

Indication:
For the acute, intermittent treatment of hypomobility, off episodes (end-of-dose wearing off and unpredictable on/off episodes) associated with advanced Parkinson’s disease.
Pharmacodynamics:
Apomorphine is a type of dopaminergic agonist, a morphine derivative which primarily affects the hypothalamic region of the brain. Drugs containing this substance are sometimes used in the treatment of Parkinson’s disease or erectile dysfunction. In higher doses it is a highly effective emetic.
Mode of Action:
The precise mechanism of action of apomorphine as a treatment for Parkinson’s disease is unknown, although it is believed to be due to stimulation of post-synaptic dopamine D2-type receptors within the brain. Apomorphine has been shown to improve motor function in an animal model of Parkinson’s disease. In particular, apomorphine attenuates the motor deficits induced by lesions in the ascending nigrostriatal dopaminergic pathway with the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in primates.
Metabolism:
Hepatic
Toxicity:
LD50=0.6 mmoles/kg (mice, intraperitoneal)
General Reference:
Matsumoto K, Yoshida M, Andersson KE, Hedlund P: Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum. Br J Pharmacol. 2005 Sep;146(2):259-67. PubmedSCHWAB RS, AMADOR LV, LETTVIN JY: Apomorphine in Parkinson’s disease. Trans Am Neurol Assoc. 1951;56:251-3. PubmedCotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I: Similarities between neurologic effects of L-dipa and of apomorphine. N Engl J Med. 1970 Jan 1;282(1):31-3. PubmedCorsini GU, Del Zompo M, Gessa GL, Mangoni A: Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson’s disease. Lancet. 1979 May 5;1(8123):954-6. PubmedChaudhuri KR, Clough C: Subcutaneous apomorphine in Parkinson’s disease. BMJ. 1998 Feb 28;316(7132):641. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization

 

  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials